I look forward to enrolling patients into the PEAK-1 trial as soon as it is open.” “The initial data for casdatifan plus cabozantinib in the ARC-20 study have already exceeded the historic ...

These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients ...

“We believe the data presented today emphasize the strength, durability and tangible therapeutic potential of our one-time infusion PRAME cell therapy, IMA203, in this patient populatio ...

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing Phase ... memory T cells ...

The oral presentation will highlight topline Phase 2 (Actuate-1801 Part 3B) data of elraglusib in combination ... our reliance on third parties to conduct our non-clinical studies and our clinical ...

All of our forecasts are generated from our proprietary forecasting system that leverages our vast amount of neighborhood weather data that we get from our community - we refer to the system as ...

Whether as a sponsor or donor, a member or volunteer, or an employee or fellow, you can make a difference. One of the pathways by which the scientific community confirms the validity of a new ...

Abstract: Accurate modeling and analytical parameter extraction of the non-quasi-static small-signal model of FinFETs are ... and extraction method is verified with the device-simulation data up to ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community. Issues are used to track todos, bugs, feature requests, and more.